Enliven Therapeutics Inc. (ELVN)
Healthcare
Biotechnology
54.80 $
+1.6%
vs. previous close
Closing price · As of: 31. Jul 2026
Enliven Therapeutics Inc. (ELVN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -19 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12 | -16 | -12 | -23 | -20 | -12 | -17 | -24 | -17 | -13 | -16 | -19 | -65 | |
| 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.3 | 0.6 | |
| 4.2 | 3.4 | 3.1 | 4.5 | 5.1 | 5.2 | 5.3 | 6.8 | 7.7 | 7.2 | 12 | 7.4 | 35 | |
| 3.4 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 1.2 | 3.2 | 5.5 | -4.6 | -4.4 | 5.0 | -0.5 | -2.5 | 0.3 | -0.2 | 1.2 | -3.4 | -2.1 | |
| 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | |
| -152 | -36 | 39 | -18 | -34 | 15 | 0.7 | 1.4 | -184 | -4.1 | 12 | 43 | -133 | |
| – | – | – | – | – | 0.3 | – | – | – | – | 0.6 | – | – | |
| -1.5 | – | – | – | – | – | – | – | – | – | – | – | – | |
| -2.8 | -0.4 | 0.1 | 90 | 1.8 | 1.1 | 40 | 0.2 | 218 | -0.4 | 0.6 | 10 | 229 | |
| -166 | -52 | 26 | 49 | -52 | 3.8 | 23 | -22 | 18 | -18 | -2.8 | 33 | 30 | |
| -12 | -16 | -12 | -23 | -20 | -12 | -17 | -24 | -17 | -13 | -16 | -19 | -66 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.